Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

As of February 28, 2015

57 joint negotiations have been **completed**** for the following drugs and indications:

Drug Product Brand Name (Generic Name)	Indication/Use *Please refer to individual jurisdictions for specific reimbursement criteria*
Adcetris (brentuximab)	Used to treat lymphoma
Adempas (riociguat)	Used to treat chronic thromboembolic pulmonary hypertension
Advair (salmeterol xinafoate/ fluticasone propionate)*	Used to treat chronic obstructive pulmonary disease and asthma
Afinitor (everolimus)	Used to treat pancreatic neuroendocrine tumours, and to treat breast cancer
Alimta (pemetrexed)	Used to treat lung cancer (new indication)
Aubagio (teriflunomide)	Used to treat relapsing-remitting multiple sclerosis
Breo Ellipta (fluticasone furoate/ vilanterol)*	Used to treat chronic obstructive pulmonary disease
Brilinta (ticagrelor)†	Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome
Dificid (fidaxomicin)	Used to treat Clostridium difficile
Effient (prasugrel)	Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome
Eliquis (apixaban)	Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis
Erivedge (vismodegib)	Used to treat metastatic basal cell carcinoma
Esbriet (pirfenidone)	Used to treat idiopathic pulmonary fibrosis
Galexos (simeprevir)	Used to treat chronic hepatitis C Genotype 1 infection
Gilenya (fingolimod)†	Used to treat relapsing-remitting multiple sclerosis
Giotrif (afatinib)	Used to treat EGFR mutation positive, advanced non-small cell lung cancer
Halaven (eribulin)	Used to treat breast cancer
Inlyta (axitinib)	Used to treat metastatic renal cell carcinoma
Jakavi (ruxolitinib)	Used to treat intermediate to high risk myelofibrosis
Jetrea (ocriplasmin)	Used to treat symptomatic vitreomacular adhesion
Kadcyla (trastuzumab emtansine)	Used to treat HER-2 positive metastatic breast cancer
Kalydeco (ivacaftor)	Used to treat cystic fibrosis
Kuvan (saproterin)†	Used to treat phenylketonuria
Lodalis (colesevelam)	Used to treat hypercholesterolemia
Mekinist (trametinib)	Used to treat metastatic melanoma
Mozobil (plerixafor)	Used in combination with *granulocyte colony-stimulating factor* to support treatment for non-Hodgkin lymphoma and multiple myeloma
Onbrez (indacaterol)†	Used as a bronchodilator for chronic obstructive pulmonary disease
Onglyza (saxagliptan)	Used to treat Type 2 diabetes mellitus
Oralair (grass pollen allergen extract)	Used to treat allergic rhinitis with or without conjunctivitis
Orencia (abatacept)	Used to treat rheumatoid arthritis

Drug Product Brand Name (Generic Name)	Indication/Use *Please refer to individual jurisdictions for specific reimbursement criteria*
Perjeta (pertuzumab)	Used to treat breast cancer
Pomalyst (pomalidomide)	Used to treat multiple myeloma
Pradaxa (dabigatran)†	Used to prevent strokes in patients with atrial fibrillation
Remicade (infliximab)*	Used to treat multiple indications including rheumatoid arthritis, ulcerative colitis and Crohn's disease
Revlimid (lenalidomide)	Used for maintenance treatment in multiple myeloma after a stem cell transplant
Seebri Breezhaler (glycopyrronium bromide)	Used to treat chronic obstructive pulmonary disease
Soliris (eculizumab)†	Used to treat paroxysmal nocturnal hemoglobinuria
Sovaldi (sofosbuvir)*	Used to treat chronic hepatitis C infection
Stivarga (regorafenib)	Used to treat metastatic and/or unresectable gastrointestinal stromal tumours (GIST)
Stribild (elvitegravir/cobicistat/ emtricitabine/tenofovir)	Used to treat HIV-1 infection in antiretroviral treatment-naïve adult patients
Sutent (sunitinib)	Used to treat pancreatic neuroendocrine tumours
Tafinlar (darafenib)	Used to treat metastatic melanoma
Tecfidera (dimethyl fumarate)	Used to treat multiple sclerosis
Treanda (bendamustine)†	Used to treat non-Hodgkin lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia
Tudorza Genuair (aclidinium bromide)	Used in management of chronic obstructive pulmonary disease (COPD)
Tysabri (natalizumab)	Used to treat relapsing-remitting multiple sclerosis
Valtrex (valacyclovir)	Used to treat specific viral infections
Votrient (pazopanib)	Used to treat metastatic renal cell carcinoma
Xalkori (crizotinib)	Used to treat advanced non-small cell lung cancer
Xarelto (rivaroxaban)†	Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis
Xarelto (rivaroxaban)	New indication for treatment of venous thromboembolic events and prevention of recurrent deep vein thrombosis and pulmonary embolism.
Xtandi (enzulatamide)	Used to treat castrate resistant prostate cancer
Yervoy (ipilimumab)†	Used to treat unresectable or metastatic melanoma
Zytiga (abiraterone)	Used to treat prostate cancer
2 drug negotiations were **closed** as agreements were not reached:	
Byetta (exenatide)	Used to treat Type 2 diabetes
Victoza (liraglutide)	Used to treat Type 2 diabetes

** A completed pan-Canadian negotiation refers to those for which a Letter of Intent (document which outlines the agreed upon terms and conditions for listing) has been signed between the lead jurisdiction for the negotiation and the manufacturer.

†The initial nine products negotiated through the pCPA.

*New negotiations completed since last update of January 31, 2015.

www.canadaspremiers.ca